Dates: April 18-22, 2026
Location: McCormick Place, Chicago, Illinois, USA
Organizer: American Academy of Neurology
Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)
The clinical trials track at AAN 2026 presents results from major ongoing and completed clinical studies in neurological disorders. This page covers key presentations across neurodegenerative diseases, stroke, epilepsy, multiple sclerosis, and neuromuscular conditions.
Alzheimer's Disease Trials
Anti-Amyloid Therapies
Lecanemab (Leqembi)
...
Dates: April 18-22, 2026
Location: McCormick Place, Chicago, Illinois, USA
Organizer: American Academy of Neurology
Website: [aanannualmeeting.com](https://www.aan.com/meetings/annual-meeting)
Overview
Mermaid diagram (expand to render)
The clinical trials track at AAN 2026 presents results from major ongoing and completed clinical studies in neurological disorders. This page covers key presentations across neurodegenerative diseases, stroke, epilepsy, multiple sclerosis, and neuromuscular conditions.
Alzheimer's Disease Trials
Anti-Amyloid Therapies
Lecanemab (Leqembi)
TRAILBLAZER-ALZ 2: Longer-term follow-up data
Real-world effectiveness: Clinical practice outcomes
ARIA management: Updated protocols and guidelines[@cummings2024]
Donanemab
TRAILBLAZER-ALZ 2: Full results and subgroup analyses
Clinical implementation: Practical considerations
Patient selection: Biomarker-guided approaches
Investigational Programs
Next-generation antibodies: Phase 2/3 results
Small molecules: Oral tau aggregation inhibitors
Combination approaches: Multi-target strategies
Anti-Tau Therapies
Immunotherapies: Longevity, JNJ-63733657
Small molecules: Tau aggregation inhibitors
Novel mechanisms: Phase 1/2 results
Prevention Trials
A4 Study: Anti-amyloid in preclinical AD
DIAN-TU: Dominantly inherited AD prevention
API: Alzheimer's Prevention Initiative
Parkinson's Disease Trials
Alpha-Synuclein Targeting
Immunotherapies
Prasinezumab: Phase 2b results and future plans
PD01A/PD03A: Active immunotherapy programs
Small Molecules
Aggregation inhibitors: Preclinical and early clinical
Disease-Modifying Therapies
LRRK2 inhibitors: Clinical development status
GBA-targeted approaches: For GBA mutation carriers
Gene Therapy
AAV-based delivery: Early-phase results
RNAi approaches: Gene silencing strategies
Stroke Trials
Acute Stroke Treatment
Thrombolysis: Extended time window studies
Thrombectomy: Patient selection criteria
Combination approaches: Bridging therapies
Stroke Prevention
Anticoagulation: Direct oral anticoagulants
Antiplatelet strategies: Dual vs. single therapy
Closure devices: PFO closure outcomes
Vascular Cognitive Impairment
Prevention strategies: Blood pressure, lifestyle
Trial design: Cognitive endpoints
Multiple Sclerosis Trials
Disease-Modifying Therapies
B-cell therapies: Ofatumumab, ocrelizumab
S1P modulators: Fingolimod, siponimod
Cladribine: Long-term safety and efficacy
Progressive MS
Ocrelizumab: Primary progressive MS results
Bruton's tyrosine kinase inhibitors
Remyelination strategies
Biomarkers
Treatment response: Predictors of efficacy
Safety monitoring: Biomarker-driven approaches
Epilepsy Trials
Antiseizure Medications
New agents: Cannabidiol, fenfluramine
Generic equivalents: Bioequivalence studies
Special populations: Pediatric, elderly
Device Therapies
Responsive neurostimulation (RNS)
Vagus nerve stimulation (VNS)
Deep brain stimulation
Surgical Approaches
Laser ablation: MR-guided stereotactic
Responsive devices: Closed-loop systems
Neuromuscular Disorders
ALS Trials
Riluzole: Real-world effectiveness
Edaravone: Clinical trial extensions
Gene therapies: SOD1, C9orf72
SMA
Onasemnogene abeparvovec: Long-term outcomes
Spinraza: Repeated dosing
Evrysdi: Real-world data
Myasthenia Gravis
Eculizumab: Generalized MG results
Rozanolixizumab: FcRn antagonists
Efgartigimod: Novel mechanisms
Clinical Trial Methodology
Biomarker Integration
Blood-based biomarkers: Screening and enrichment
Imaging biomarkers: Patient selection
Digital biomarkers: Remote monitoring
Trial Design Innovations
Platform trials: Master protocols
Adaptive designs: Sample size re-estimation
Hybrid designs: Traditional and real-world evidence
Regulatory Updates
FDA guidance: Alzheimer's disease endpoints
EMA perspectives: European regulatory views
Patient-reported outcomes: Novel endpoints
Related Conference Content
[AAN 2026](/events/aan-2026) — Main conference page](/events)
[AAN 2026 Alzheimer's and Parkinson's Updates](/events/aan-2026-alzheimers-parkinsons-updates)](/events)